Table 5.

Number of patients who reported neurotoxicity symptoms at each time point.

Assessment time points	Dose Level −I						Dose Level II						Feasibility phase
	N	No. of Ntx symptoms					N	No. of Ntx symptoms					N	No. of Ntx symptoms
		0	1	2	3	4		0	1	2	3	4		0	1	2	3	4
Prior to cycle 1	6	6					3	2	1				25	24	1
Prior to cycle 2	6	4		2			3	2		1			21	17	1	2		1
Prior to cycle 3	6	3	1	2			3	1	1	1			17	9	4	1	1	2
Prior to cycle 4	6	4	2				3	1	1			1	16	8	2	4		2
Prior to cycle 5	6	4	1	1			3		1		1	1	17	11	2	2		2
Prior to cycle 6	6	4	1			1	2					2	16	8	2	1	2	3
3 month post treatment	6	2	2	1	1		3	1		1		1	17	10	2	3		2
6 months post treatment	4	4					3	1	1			1	18	9	3	2	1	3
9 months post treatment	2	1				1	2					2	16	5	5	5	1
12 months post treatment	3	2				1	3			2		1	14	7	1	4	1	1

N: Number of patients who completed Ntx survey.